Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 3 for:    premia spine
Previous Study | Return to List | Next Study

A Pivotal Study of the Premia Spine TOPS™ System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03012776
Recruitment Status : Active, not recruiting
First Posted : January 6, 2017
Last Update Posted : September 28, 2022
Information provided by (Responsible Party):
Premia Spine

Brief Summary:

The purpose of this trial is to assess whether the Total Posterior Spine System (TOPS System) is more effective than transforaminal lumbar interbody fusion (TLIF) when used to stabilize a single lumbar level (L2 - L5) following surgical decompression in patients diagnosed with (1) at least moderate lumbar spinal stenosis, and (2) Grade 1 spondylolisthesis (or retrolisthesis), and (3) thickening of the ligamentum flavum or scarring of the facet joint capsule.

Success will be assessed by means of a composite endpoint that measures improvement in in patient reported outcomes and the absence of any major device related complications.

Condition or disease Intervention/treatment Phase
Lumbar Spinal Stenosis Degenerative Spondylolisthesis Device: Total Posterior Spine System (TOPS) Procedure: Transforaminal Lumbar Interbody Fusion (TLIF) Not Applicable

Detailed Description:

Degenerative spine disease is a normal part of the aging process and can cause pain and significantly limit normal movement. The most commonly diagnosed condition is Lumbar Spinal Stenosis (LSS) which presents with pain, and often weakness or numbness in the buttocks and/or lower extremities that is worsened with standing and walking. For patients that do not respond to conservative treatment decompressive surgery is indicated. When LSS is accompanied by a diagnosis of degenerative spondylolisthesis, fusion of the affected segment is often added to prevent progression of the instability that may accompany the removal of bony elements as part of the decompression. While decompression and fusion have been shown to significantly improve patient outcomes, when compared to decompression alone, fusion has been associated with several comorbidities such as adjacent level degeneration and pseudoarthrosis.

The TOPS System was designed as an alternative to fusion and is a motion preserving posterior spine implant designed to provide dynamic stabilization to a single lumbar spine segment following decompression surgery.

Patients meeting all of the entry criteria will be randomized (2:1) to receive either the TOPS System or TLIF following decompression surgery. Patients will be followed for 5 years and the composite primary endpoint will be assessed at 2 years following index surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 305 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS™ System
Actual Study Start Date : July 17, 2017
Actual Primary Completion Date : June 27, 2022
Estimated Study Completion Date : June 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Spinal Stenosis

Arm Intervention/treatment
Experimental: TOPS System
Investigational surgical treatment using TOPS System
Device: Total Posterior Spine System (TOPS)
Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis

Active Comparator: Transforaminal Lumbar Interbody Fusion (TLIF)
Control surgical treatment using interbody fusion and placement of posterolateral instrumentation
Procedure: Transforaminal Lumbar Interbody Fusion (TLIF)
Fusion with placement of interbody cage and posterolateral instrumentation

Primary Outcome Measures :
  1. Improvement in Oswestry Disability Index (ODI) [ Time Frame: 24 months ]
  2. Maintenance or improvement in Neurological status as assessed by a standard neurological exam performed by Investigator [ Time Frame: 24 months ]
  3. No epidural steroid injection, facet joint injection, nerve block, or placement of spinal cord stimulator [ Time Frame: 24 months ]
  4. No subsequent surgical intervention [ Time Frame: 24 months ]
  5. Radiographic confirmation of fusion in control arm and non-fusion in the TOPS arm [ Time Frame: 24 months ]
  6. Absence of any major device related adverse event [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Greater range-of-motion through flexion-extension [ Time Frame: 24 months ]
  2. Improvement (20 mm) in visual analogue scale (VAS) for back pain and worst leg [ Time Frame: 24 months ]
  3. Reduction in physical component score on SF-12 [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be between 35 and 80 years of age;
  • Must demonstrate at a single level to be treated (L2/3, L3/4 or L4/5) all three of the following;

    1. Degenerative spondylolisthesis or retrolisthesis up to Grade I, as determined by the investigator based on flexion/extension X-rays,
    2. At least moderate lumbar spinal stenosis, defined as at least a 25% reduction in either the central canal, the lateral recess space, and/or the foramen when compared to an adjacent level, as determined by the investigator based on MRI,
    3. Thickening of the ligamentum flavum and/or scarring of the facet joint capsule as identified by the investigator based on MRI.
  • Have had at least six (6) months of failed conservative treatment prior to surgery (e.g., physical therapy, use of anti-inflammatory medications at maximum recommended dosage; administration of epidural/facet injections and/or nerve block);
  • Have an Oswestry Disability Index (ODI) score of at least 40/100 at baseline;
  • Have leg pain with a VAS score of at least 40/100 for at least one leg at baseline ;
  • Lower back pain with a VAS score of at least 10 points less than Worst Leg VAS score;
  • Neurogenic claudication (as defined by worsening leg pain when walking or standing, which is reduced when sitting or bending forward);

Exclusion Criteria:

  • Presence of free fragment disc herniation at the index level or either adjacent level;
  • Less than 4mm of disc height at the index level;
  • Spondylolisthesis greater than Grade I;
  • Back or non-radicular leg pain of unknown etiology;
  • Stenosis caused by an extruded spinal disc fragment (e.g., herniation) or where the etiology is considered to be congenital, iatrogenic, post-traumatic, or metabolic;
  • Known allergy or sensitivity to PEEK, titanium, cobalt chrome, and/or polyurethane;
  • Prior surgery at any lumbar vertebral level with instrumentation;
  • Prior surgery at the index or adjacent lumbar vertebral level;
  • Clinically compromised vertebral bodies at the affected level;
  • Scoliosis greater than ten (10) degrees by major Cobb angle;
  • BMI > 40;
  • Osteoporosis;
  • Paget's disease, gout, osteomalacia, osteogenesis imperfecta, thyroid and/or parathyroid gland disorder and/or other metabolic bone disease;
  • Active infection - systemic or local;
  • Active hepatitis;
  • AIDS, HIV, Rheumatoid arthritis or other autoimmune disease;
  • Tuberculosis - active or in the past 3 years;
  • Active malignancy;
  • Any medical condition requiring treatment with any drug known to potentially interfere with bone/soft tissue healing or receiving radiation therapy that is expected to continue for the duration of the study;
  • Cauda equina syndrome or neurogenic bowel/bladder dysfunction;
  • Vascular claudication due to severe arterial insufficiency of the legs;
  • Sustained pathologic lumbar fractures of the vertebra or multiple lumbar fractures of the vertebra or hip;
  • Significant peripheral neuropathy causing decreased sensation in a stocking-like or non-radicular and non-dermatomal distribution in the lower extremities;
  • Insulin-dependent diabetes mellitus;
  • Immunologically suppressed, receiving steroids > 1 month out of the past year;
  • Current chemical/alcohol dependency;
  • Current smoker or user of tobacco products;
  • Pregnant or interested in becoming pregnant;
  • Currently involved in active spinal litigation;
  • Currently having a workman's compensation claim;
  • Currently incarcerated;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03012776

Show Show 36 study locations
Sponsors and Collaborators
Premia Spine
Layout table for additonal information
Responsible Party: Premia Spine Identifier: NCT03012776    
Other Study ID Numbers: CL-2830 - US IDE
First Posted: January 6, 2017    Key Record Dates
Last Update Posted: September 28, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Stenosis
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases